+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
FEMALE
ID06611813

Phase II Study of Toripalimab Combined with Chemotherapy for HRHER2- Breast Cancer in Women Aged 18 to 75

Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-12

30

Participants Needed

11

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to assess the effects of combining Toripalimab with neoadjuvant chemotherapy in women with hormone receptor-positive, HER2-negative HRHER2- breast cancer. This phase II, single-arm, multi-center study focuses on evaluating the rate of complete tumor response after treatment and the ratio of residual cancer burden RCB 0-1. It also tracks the occurrence and types of side effects, while observing long-term outcomes such as disease-free survival, progression-free survival, and objective response rate. Participants will receive a combination of chemotherapy drugs and the monoclonal antibody Toripalimab. The chemotherapy consists of two phases the first includes intravenous Epirubicin or liposomal Doxorubicin plus Cyclophosphamide given weekly for 12 weeks, and the second phase uses Paclitaxel every three weeks for another 12 weeks. Toripalimab is administered intravenously at 240 mg every three weeks during both the neoadjuvant chemotherapy phase and the postoperative adjuvant therapy, continuing for a total of one year. During the study, participants will undergo evaluations to monitor treatment response and side effects. Researchers will assess tumor pathology to measure complete response and residual cancer burden after two years. They will also track survival outcomes over three years. Safety monitoring includes blood tests, cardiac ultrasound, electrocardiograms, and managing adverse events carefully. Participants are expected to comply with follow-up visits and treatment schedules throughout the study period.

CONDITIONS

Brief Title

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Research Team

Z

Zhijun Dai

Y

Youyi Chen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here